Cuprina Holdings (Cayman) Limit (NASDAQ:CUPR)
| Market Cap | 4.29M-85.7% |
| Revenue (ttm) | 26.79K |
| Net Income | -2.69M |
| EPS | -1.00 |
| Shares Out | 2.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,282,062 |
| Open | 1.56 |
| Previous Close | 2.93 |
| Day's Range | 1.45 - 1.79 |
| 52-Week Range | 1.45 - 14.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About CUPR
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
$CUPR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CUPR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CUPR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CUPR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CUPR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CUPR from public contracts
Source: USAspending.gov
CUPR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CUPR’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.